TY - JOUR
KW - Dopamine
KW - Genetic Predisposition to Disease
KW - Genotype
KW - Humans
KW - Methylenetetrahydrofolate Reductase (NADPH2)/genetics
KW - Opioid-Related Disorders/epidemiology/genetics
KW - Polymorphism, Single Nucleotide
KW - Prevalence
KW - Retrospective Studies
KW - Tennessee
KW - Methylenetetrahydrofolate reductase (MTHFR) gene
KW - Addiction
KW - opioid use disorder
AU - L. Cole
AU - A. Cernasev
AU - K. Webb
AU - S. Kumar
AU - A. S. Rowe
A1 - 
AB - Background: Opioid Use Disorder (OUD) has been linked to dopamine and the neurological reward centers. Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the production of many neurotransmitters such as dopamine. As such, MTHFR variants that lead to decreased production of neurotransmitters may play a role in OUD. However, lacunae exist for characterizing the prevalence of the MTHFR mutations in an OUD population. The objective of this study was to determine prevalence of the MTHFR gene mutations in a rural Tennessean population with OUD. Methods: This study was a retrospective cohort of individuals with OUD that evaluated the prevalence of MTHFR variants. Patients were categorized as normal, homozygous C677T, heterozygous C677T, homozygous A1298C, or heterozygous A1298C. The primary outcome was a qualitative comparison of the prevalence of each of the MTHFR variants in our cohort to the publicly reported MTHR polymorphism prevalence. Secondary outcomes include race and ethnicity differences as well as stimulant use differences for each of the variants. Results: A total of 232 patients undergoing care for opioid use disorder were included in the study. Of those included, 30 patients had a normal MTHFR allele and 202 had a variant MTHFR allele. Overall, the prevalence of any MTHFR variant was 87.1% (95% CI 82.6-91.4%). When comparing those with a normal MTHFR allele to those with any MTHFR variant, there was no difference in age, sex, race and ethnicity, or stimulant use. Conclusion: The overall prevalence of MTHFR variants in patients with opioid use disorders is high.
AD - Pathway Healthcare, LLC, 801 Hill Street, Springfield, TN 37172, USA.; Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, 301 S. Perimeter Park Drive, Suite 220, Nashville, TN 37211, USA.; Pathway Healthcare, LLC, 1000 Urban Center Drive, Suite 600, Birmingham, AL 35242, USA.; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Ave, Memphis, TN 38163, USA.; Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Science Center, 1924 Alcoa Hwy, Box 117, Knoxville, TN 37920, USA.
BT - International journal of environmental research and public health
C5 - Healthcare Disparities; Opioids & Substance Use
CP - 6
DO - 10.3390/ijerph19063255
IS - 6
JF - International journal of environmental research and public health
LA - eng
M1 - Journal Article
N2 - Background: Opioid Use Disorder (OUD) has been linked to dopamine and the neurological reward centers. Methylenetetrahydrofolate reductase (MTHFR) is an enzyme involved in the production of many neurotransmitters such as dopamine. As such, MTHFR variants that lead to decreased production of neurotransmitters may play a role in OUD. However, lacunae exist for characterizing the prevalence of the MTHFR mutations in an OUD population. The objective of this study was to determine prevalence of the MTHFR gene mutations in a rural Tennessean population with OUD. Methods: This study was a retrospective cohort of individuals with OUD that evaluated the prevalence of MTHFR variants. Patients were categorized as normal, homozygous C677T, heterozygous C677T, homozygous A1298C, or heterozygous A1298C. The primary outcome was a qualitative comparison of the prevalence of each of the MTHFR variants in our cohort to the publicly reported MTHR polymorphism prevalence. Secondary outcomes include race and ethnicity differences as well as stimulant use differences for each of the variants. Results: A total of 232 patients undergoing care for opioid use disorder were included in the study. Of those included, 30 patients had a normal MTHFR allele and 202 had a variant MTHFR allele. Overall, the prevalence of any MTHFR variant was 87.1% (95% CI 82.6-91.4%). When comparing those with a normal MTHFR allele to those with any MTHFR variant, there was no difference in age, sex, race and ethnicity, or stimulant use. Conclusion: The overall prevalence of MTHFR variants in patients with opioid use disorders is high.
PY - 2022
SN - 1660-4601; 1661-7827; 1660-4601
SP - 3255. doi: 10.3390/ijerph19063255
T1 - A Study of the MTHFR Gene Prevalence in a Rural Tennessee Opioid Use Disorder Treatment Center Population
T2 - International journal of environmental research and public health
TI - A Study of the MTHFR Gene Prevalence in a Rural Tennessee Opioid Use Disorder Treatment Center Population
U1 - Healthcare Disparities; Opioids & Substance Use
U2 - 35328943
U3 - 10.3390/ijerph19063255
VL - 19
VO - 1660-4601; 1661-7827; 1660-4601
Y1 - 2022
Y2 - Mar 10
ER -